Shares of Johnson & Johnson (NYSE: JNJ) were up more than 3.8% at $128.16 in early trading today, after the US healthcare giant announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020.
This marks a significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of J&J and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of the company's manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze